Alumis Inc. is a cutting-edge technology company specializing in the development and commercialization of innovative solutions within the healthcare sector. Focused on enhancing patient care and operational efficiencies, the company harnesses advanced data analytics and artificial intelligence to provide healthcare providers with actionable insights and tools. Their offerings aim to improve patient outcomes, streamline workflows, and reduce costs, positioning Alumis as a key player in the transformation of healthcare services. Through their commitment to research and development, the company strives to address the evolving needs of the medical community and empower healthcare professionals with the resources necessary for excellence in care delivery. Read More
ACELYRIN stockholders to receive increased ownership in the combined company through revised exchange ratio; Alumis and ACELYRIN stockholders to now own approximately 52% and 48%, respectively, of the combined company on a fully diluted basis
Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis.
Curious to know what's happening on the US markets one hour before the close of the markets on Tuesday? Join us as we explore the top gainers and losers in today's session.
Looking for insights into the US markets one hour before the close of the markets on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Alumis stock is trading higher on Tuesday after the company announced it entered into a collaboration and licensing agreement with Kaken Pharmaceuticals.
